{"title": "Weekly diabetes drug provides similar benefits to daily version", "text": "A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling type 2 diabetic patients' blood sugar as a daily DPP-4 inhibitor in a recent randomized clinical trial.The drug, called omarigliptin, offers the prospect of a more convenient treatment for patients with diabetes.\"The observed glycaemic efficacy in the present study indirectly serves as further evidence of the feasibility of providing DPP-4 inhibition over the period of 1 week with a single once-weekly dose that is similar to that which can be achieved with daily administration,\" wrote the authors of the Diabetes, Obesity and Metabolism study.\r\n", "article_link": "http://dx.doi.org/10.1111/dom.12832", "url": "http://www.eurekalert.org/pub_releases/2017-01/w-wdd011717.php", "region": "namerica", "source_link": null, "funder": "", "meeting": "", "institution": "Wiley", "keywords": ["Medicine/Health", " Clinical Trials", " Diabetes"], "journal": "Diabetes, Obesity and Metabolism", "description": "A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling type 2 diabetic patients' blood sugar as a daily DPP-4 inhibitor in a recent randomized clinical trial.", "date": "Tue, 17 Jan 2017 05:00:00 GMT"}